Home > Browse Issues > Vol.39 No.8
The Mechanism and Clinical Status of Bone Marrow Mononuclear Cell Therapy for Myocardial Infarction
Wang Xianyun1, Zhai Congjie2, Jiang Xifeng3, Yan Baoyong3, Li Quanhai1,4*, Liu Gang5*
1Cell Therapy Laboratory, the First Hospital of Hebei Medical University, Shijiazhuang 050030, China; 2Department of General Surgery, the First Hospital of Hebei Medical University, Shijiazhuang 050030, China; 3Research Center of Engineering and Technology for Stem Cell Application, Shijiazhuang 050000, China; 4Department of Immunology, Basic Medical College, Hebei Medical University, Shijiazhuang 050017, China; 5Department of Cardiology, the First Hospital of Hebei Medical University, Shijiazhuang 050030, China)
Abstract: Myocardial infarction is a leading cause of death among all cardiovascular diseases. Bone marrow mononuclear cells (BMMNCs) have become one of the candidate seed cells in treatment of myocardial infarction because of its advantages of easy separation and no immune rejection. The previous experiments in vivo have proved the improved cardiac blood circulation and systolic function in animal models after BMMNCs transplantation by producing the secretions of growth factors and other proteins to promote angiogenesis， balancing the immunological system and stimulating cardiac muscle regeneration. Although the animal experiments have demonstrated the effectiveness of BMMNCs， the conflicting results have occurred in many clinical trials. Therefore， this article will respectively review the progress of the primary mechanism of BMMNCs， the clinical status of BMMNCs and the major influencing factors in the treatment of myocardial infarction.
CN
EN